Skip to main content
SpringerLink
Log in

Nebenwirkungen der Chemotherapie

Side effects of chemotherapy

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Der Einsatz multimodaler Therapiekonzepte für urologische Tumorerkrankungen konfrontiert den Urologen zunehmend mit den Nebenwirkungen der medikamentösen Therapie. Zu den häufigsten Nebenwirkungen der Chemotherapie gehören die Neutropenie, Stomatitis, Mukositis, Diarrhö und die Emesis. Gute Prophylaxe und ein standardisiertes Nebenwirkungsmanagement verbessern die Effizienz der Therapie.

Abstract

Urologic tumors are frequently treated by multimodal therapeutic strategies with the consequence of an increasing number of adverse events. The most common chemotherapy-induced side effects are neutropenia, stomatitis, mucositis, diarrhea, and emesis. The efficacy of tumor therapy can be improved by good prophylaxis and standardized management of side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Maroun JA, Anthony LB, Blais N et al (2007) Prevention and management of chemotherapy induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Curr Oncol 14(1):13–20

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Vehreschild MJGT et al (2013) Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Oncol 24(5):1189–1202

    Article  CAS  PubMed  Google Scholar 

  3. Schöffski P (2006) Prävention und Therapie von Organtoxizitäten im Gastrointestinaltrakt. In: Schmoll HJ, Höffken K, Possinger K (Hrsg) Kompendium Internistische Onkologie, 4. Aufl. Springer, Heidelberg

    Google Scholar 

  4. Benson AB 3rd, Ajani JA, Catalano RB et al (2004) Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22(14):2918–2926

    Article  CAS  PubMed  Google Scholar 

  5. Dörr W, Haagen J, Hartmann JT, Riesenbeck D, Schmidt M, Grötz KA (2010) Behandlung der oralen Mukositis in der Onkologie. Was ist wirklich wirksam? MMW Fortschr Med. 152(46):37–39

    Article  Google Scholar 

  6. Dörr W, Hartmann JT, Riesenbeck D, Grötz KA (2009) Mundschleimhaut. In: Feyer P, Ortner P (Hrsg) Supportivtherapie in der Onkologie. Urban & Vogel, München, S 72–85

    Google Scholar 

  7. Jordan K, Gralla R, Jahn F, Molassiotis A (2014) International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 722:197–202. doi:10.1016/j.ejphar.2013.09.073

    Article  CAS  PubMed  Google Scholar 

  8. Loblaw DA, Prestrud AA, Somerfield MR, Oliver TK, Brouwers MC, Nam RK, Lyman GH, Basch E (2012) American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. J Clin Oncol 30(25):3136–3140. doi:10.1200/JCO.2012.42.0489

    Article  PubMed  Google Scholar 

  9. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D, ESMO/MASCC Guidelines Working Group (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232–v243. doi:10.1093/annonc/mdq194

    Article  PubMed  Google Scholar 

  10. Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21(6):1655–1663. doi:10.1007/s00520-012-1710-6

    Article  PubMed  Google Scholar 

  11. Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25(7):1328–1333. doi:10.1093/annonc/mdu101

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ettinger DS, Dwight D, Kris MG (2013) National comprehensive cancer network: antiemesis, Clinical Practice Guidelines in Oncology, 1. Aufl. NCCN, Jenkintown

    Google Scholar 

  13. Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, Kuderer NM, Langston AA, Marr KA, Rolston KV, Ramsey SD (2013) Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31(6):794–810. doi:10.1200/JCO.2012.45.8661

    Article  PubMed  Google Scholar 

  14. Crawford J, Armitage J, Balducci L, Becker PS, Blayney DW, Cataland SR, Heaney ML, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Steensma DP, Talbott M, Vadhan-Raj S, Westervelt P, Westmoreland M, Dwyer M, Ho M (2013) National comprehensive cancer network. Myeloid growth factors. J Natl Compr Canc Netw 11(10):1266–1290

    CAS  PubMed  Google Scholar 

  15. Crawford J, Caserta C, Roila F, ESMO Guidelines Working Group (2010) Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol 21(Suppl 5):v248–v251. doi:10.1093/annonc/mdq195

    Article  PubMed  Google Scholar 

  16. Muñoz Langa J, Gascón P, de Castro J, SEOM (Spanish Society of Clinical Oncology) (2012) SEOM clinical guidelines for myeloid growth factors. Clin Transl Oncol 14(7):491–498. doi:10.1007/s12094-012-0830-2

    Article  PubMed  Google Scholar 

  17. Link H (2006) Therapie mit den hämatopoetischen Wachstumsfaktoren G‑CSF und GM-CSF. In: Schmoll HJ, Höffken K, Possinger K (Hrsg) Kompendium Internistische Onkologie, 4. Aufl. Springer, Heidelberg

    Google Scholar 

  18. Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, On behalf of the participants of the MASCC/ESMO Consensus Conference Copenhagen 2015, - (2016) MASCC and ESMO Consensus Guidelines for the prevention of chemotherapy and radiotherapy-induced nausea and vomiting: ESMO Clinical Practice Guidelines. Ann Oncol 27(suppl 5):v119–v133

    Article  CAS  PubMed  Google Scholar 

  19. Sweeney CJ, Chen Y‑H, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong Y‑N, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS (2015) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 373:737–746. doi:10.1056/NEJMoa1503747

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Retz M, Gschwend JE (2009) Medikamentöse Tumortherapie in der Uroonkologie. Springer, Berlin

    Book  Google Scholar 

  21. Aapro M, Rugo H, Rossi G et al (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25:1328–1333

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. James ND et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387(10024):1163–1177

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. MASCC Leitlinie Antiemese ESMO 2016

Download references

Author information

Authors and Affiliations

  1. Urologische Klinik und Poliklinik, Klinikum rechts der Isar, Technischen Universität München, Ismaninger Str. 22, 81675, München, Deutschland

    K. Hauner,  P. Maisch &  M. Retz

Authors
  1. K. Hauner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Maisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Retz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Hauner.

Ethics declarations

Interessenkonflikt

K. Hauner gibt Vortragsvergütungen und Reiseunterstützung von Astellas Pharma GmbH, Janssen-Cilag GmbH, Pfizer GmbH an. P. Maisch gibt Vortragsvergütungen und Honorare von Vortragsvergütungen von Pierre-Fabre Pharma GmbH und Reiseunterstützung von Bristol-Myers Squibb an. M. Retz gibt Vortragsvergütungen und Honorare von Astellas Pharma GmbH, Janssen-Cilag GmbH, Pfizer GmbH, BMS, Roche, MSD an.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

K. Hauner, P. Maisch und M. Retz repräsentieren die Arbeitsgemeinschaft Urologische Onkologie der Deutschen Krebsgesellschaft (AUO).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hauner, K., Maisch, P. & Retz, M. Nebenwirkungen der Chemotherapie. Urologe 56, 472–479 (2017). https://doi.org/10.1007/s00120-017-0338-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-017-0338-z

Schlüsselwörter

Keywords

Search

Navigation